Biological Half-Life

Biological Half-Life designates the time required for a biological system to eliminate half of an administered substance through all processes including metabolism, excretion, and non-enzymatic degradation, representing a composite parameter reflecting all elimination mechanisms rather than any single pathway, and determining dosing frequency requirements for maintaining therapeutic concentrations.

The pharmaceutical industry characterises biological half-life throughout pharmacokinetic development to inform dosing regimen design, understand elimination mechanisms, and guide formulation strategies. Short half-life drugs require frequent dosing or controlled-release formulations. Long half-life allows less frequent administration but may complicate dose titration and extend time to steady-state. Biologics exhibit diverse half-lives from minutes for small peptides to weeks for IgG antibodies exploiting FcRn recycling. Half-life extension strategies including PEGylation, albumin fusion, and Fc engineering have transformed dosing convenience for numerous biologics. Population pharmacokinetic analysis identifies patient factors affecting half-life enabling dose individualisation.